Literature DB >> 11692231

Characterization of a novel Kv1.5 channel blocker in Xenopus oocytes, CHO cells, human and rat cardiomyocytes.

A Bachmann1, I Gutcher, K Kopp, J Brendel, R F Bosch, A E Busch, H Gögelein.   

Abstract

The inhibitory effects of the novel Kv1.5 channel blocker, S9947 (2'-(benzyloxycarbonylaminomethyl)biphenyl-2-carboxylic acid 2-(2-pyridyl)ethylamide), on cloned human Kv1.5 (hKv1.5), expressed in both Xenopus oocytes and Chinese hamster ovary (CHO) cells, and on native cardiac ultrarapid delayed rectifier potassium currents (IKur) in rat (ventricle myocytes) and human (atrial myocytes) were investigated. The influence of S9947 on the action potential was examined in rat ventricular myocytes. Using the two-electrode voltage-clamp technique in Xenopus oocytes and the patch-clamp technique (whole cell configuration) in CHO cells, hKv1.5 was inhibited by S9947 with IC50 values of 0.65 microM and 0.42 microM, respectively. In addition, inhibition of human Kv4.3 (hKv4.3) and HERG by 10 microM S9947 was low (approximately 20%) and absent, respectively. Using the patch-clamp technique in the whole cell configuration, IKur currents in rat ventricular (rIKur) cardiomyocytes and human atrial (hIKur) cardiomyocytes were inhibited by S9947 with IC50 values of 0.96 microM and 0.07 microM, respectively. In contrast, rat cardiac inward rectifier current (rIK1) and rat (rIto) and human (hIto) cardiac transient outward currents were only inhibited by approximately 20% with 10 microM S9947. In rat cardiomyocytes, using the patch-clamp technique, action potential duration was increased by S9947 in a concentration-dependent (0.3-10 microM) and rate-independent manner. The data show that S9947 suppresses both cloned (Kv1.5) and native (IKur) cardiac potassium currents. Furthermore, S9947 prolongs rat action potential in a rate-independent manner.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11692231     DOI: 10.1007/s002100100474

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  5 in total

1.  Kv1.5 blockers preferentially inhibit TASK-1 channels: TASK-1 as a target against atrial fibrillation and obstructive sleep apnea?

Authors:  Aytug K Kiper; Susanne Rinné; Caroline Rolfes; David Ramírez; Guiscard Seebohm; Michael F Netter; Wendy González; Niels Decher
Journal:  Pflugers Arch       Date:  2014-12-17       Impact factor: 3.657

2.  Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels.

Authors:  Heinz Gögelein; J Brendel; K Steinmeyer; C Strübing; N Picard; D Rampe; K Kopp; A E Busch; M Bleich
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-08-31       Impact factor: 3.000

3.  Disease and region-related cardiac fibroblast potassium current variations and potential functional significance.

Authors:  Chia-Tung Wu; Xiao-Yan Qi; Hai Huang; Patrice Naud; Kristin Dawson; Yung-Hsin Yeh; Masahide Harada; Chi-Tai Kuo; Stanley Nattel
Journal:  Cardiovasc Res       Date:  2014-03-04       Impact factor: 10.787

4.  The effects of jaspamide on human cardiomyocyte function and cardiac ion channel activity.

Authors:  Karen Schweikart; Liang Guo; Zachary Shuler; Rory Abrams; Eric T Chiao; Kyle L Kolaja; Myrtle Davis
Journal:  Toxicol In Vitro       Date:  2012-12-20       Impact factor: 3.500

5.  Potassium Channels Kv1.3 and Kir2.1 But Not Kv1.5 Contribute to BV2 Cell Line and Primary Microglial Migration.

Authors:  Ruxandra Anton; Mihail Ghenghea; Violeta Ristoiu; Christophe Gattlen; Marc-Rene Suter; Petre Alexandru Cojocaru; Aurel Popa-Wagner; Bogdan Catalin; Alexandru-Florian Deftu
Journal:  Int J Mol Sci       Date:  2021-02-19       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.